Check out this issue’s free to access editorial, in which Ernest Moles & Xavier Fernàndez-Busquets (Institute for Bioengineering of Catalonia, Spain) propose targeting healthy red blood cells with anti-malarial drugs so that when the pathogen enters the host cell, it encounters its enemy at home, right at the very moment of entry.
This issue also features Editorial Board Member, John Baldwin’s (Cleo Pharmaceuticals, USA) annual roundup of 2014’s mergers, acquisitions, alliances and research emerging from Big Pharma. Find the article here.
Also in this issue is a Review by Ferreira et al. (University of Lisbon, Portugal), which discusses the role of the plasma membrane in multi-drug resistance, in addition to original research from Cerecetto et al. (University of the Republic , Uruguay) on the potential of phase II enzymes inducers in cancer therapy . The full content can be seen here.